Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Agilysys Inc (AGYS) vs Medpace Holdings Inc (MEDP) Price & Performance

Agilysys IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Agilysys Inc vs Medpace Holdings Inc — how do they compare? Agilysys Inc trades at $107.52 (market cap $3.00B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 5.6× Agilysys Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Agilysys Inc nearer its low. Which is the better fit depends on your goals.

AGYSMEDP
Market Cap
$3.00B$16.90B
Sector
TechnologyTechnology
52-Week High
$141.12$620.59
52-Week Low
$62.19$393.42
Enterprise Value
$2.90B$16.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Agilysys Inc

Agilysys (AGYS) trades at $107.35, up 0.35% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q1 and Q2 2026 earnings beats, record subscription revenue growth, and improved FY27 guidance. Technical indicators suggest bullish momentum with support at $106 and resistance at $108. The company's hospitality software solutions are gaining traction through partnerships and AI-driven innovation.

Outlook remains positive with 100% analyst buy ratings and $118.33 consensus price target representing 10.2% upside. Key opportunities include subscription revenue growth and Marriott deployment progress, while risks include execution challenges and competitive pressures in the hospitality technology sector.

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Agilysys Inc

Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.

Read more on AGYS

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP